Under the leadership of Gabriele Grecchi, CEO and Co-Founder, alongside Antonio Alessandrino, Chief Technology Officer and Founder, KLISBio will showcase its latest advancements in peripheral nerve repair, highlighting the SILKBridge® Nerve Guide (product not yet cleared nor available for commercial sale in the US, EU or other countries). Joining them at booth #5 will be Gabriella Francavilla, Senior Marketing and Communications Manager, and Alisia Corinne Fiore, Marketing and Communications Specialist, offering demonstrations of SILKBridge®. Their primary goal is to engage with physicians and strategic partners, nurturing existing connections and forging new ones, with the aim of initiating discussions with potential Early Adopters interested in participating in the European Clinical study for CE Mark approval.

SILKBridge®, a silk fibroin absorbable medical device for peripheral nerve repair, is the most advanced product in KLISBio’s pipeline. The results of a long-term follow up on SILKBridge® Nerve Guide, conducted by Prof. Maurizio Calcagni, former Deputy Clinic Director at Department of Plastic Surgery and Hand Surgery at University Hospital Zurich , will be presented on May 9th during the ISPNR 2024 joint session Basic Scientists meet surgeons in peripheral nerve regeneration and repair.

The patented 3D architecture of SILKBridge® shows two working mechanisms in one device. SILKBridge® multilayered structure has an optimized balance between biomechanical and biological properties, complementing the high strength of native silk fibers and the enhanced biomimicry of electrospun silk. The inner and outer electrospun layers are specifically designed to promote cell adhesion and resorb faster. The morphological properties of electrospun fibers mimic the nanoscale structure of the extracellular matrix. The intermediate textile layer is made of a textile component and is designed to confer high mechanical performance and resistance to the device and to resorb at a slower rate.

"The promising functional and patient satisfaction results revealed in the long-term follow-up of the premarket, monocenter first-in-human pilot study on SILKBridge® mark a significant milestone. This sets the stage for KLISBio's future clinical strategy development,including the pivotal clinical trial we are planning for 2025.", said Antonio Alessandrino, CTO and Founder.

"KLISBio is fully dedicated to advancing the field of peripheral nerve repair through rigorous clinical research and development initiatives. Our commitment extends to the implementation of a future comprehensive Clinical Study in the EU to secure the CE Mark for SILKBridge®, affirming its safety and efficacy in clinical practice. Additionally, we are steadfast in our efforts to address the evolving needs of patients and market demands by expanding our R&D focus. This includes the development of new sizes of SILKBridge®, ensuring that we continue to provide innovative solutions that improve patient outcomes and transform the landscape of peripheral nerve repair.", added Gabriele Grecchi, CEO of KLISBio.

KLISBio holds two patents and trade secrets in covering a variety of silk-based technologies. The Company is powered by a group of world leaders in MedTech including Grecchi, CEO, Antonio Alessandrino, Chief Technology Officer and Giuliano Freddi, Chief Scientific Officer, Rodrigo Bianchi, serving as Chairman of the Board with more than three decades of experience in global healthcare. In addition to its strong leadership team, KLISBio works with physicians, engineers, researchers, chemists and biologists worldwide who represent excellence in the biomedical space.